BA3 Stock Overview
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BA3 from our risk checks.
Azenta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.60 |
| 52 Week High | US$62.50 |
| 52 Week Low | US$37.60 |
| Beta | 1.48 |
| 11 Month Change | 15.34% |
| 3 Month Change | -0.91% |
| 1 Year Change | -16.15% |
| 33 Year Change | -56.40% |
| 5 Year Change | 6.86% |
| Change since IPO | -16.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| BA3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 9.0% | 0.9% | -0.02% |
| 1Y | -16.2% | 2.7% | 8.2% |
Return vs Industry: BA3 underperformed the German Life Sciences industry which returned 2.7% over the past year.
Return vs Market: BA3 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| BA3 volatility | |
|---|---|
| BA3 Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: BA3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BA3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 3,300 | John P. Marotta | www.azenta.com |
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions.
Azenta, Inc. Fundamentals Summary
| BA3 fundamental statistics | |
|---|---|
| Market cap | €1.98b |
| Earnings (TTM) | -€157.65m |
| Revenue (TTM) | €630.27m |
3.1x
P/S Ratio-12.5x
P/E RatioIs BA3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BA3 income statement (TTM) | |
|---|---|
| Revenue | US$656.32m |
| Cost of Revenue | US$388.99m |
| Gross Profit | US$267.34m |
| Other Expenses | US$431.51m |
| Earnings | -US$164.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.60 |
| Gross Margin | 40.73% |
| Net Profit Margin | -25.01% |
| Debt/Equity Ratio | 0% |
How did BA3 perform over the long term?
See historical performance and comparison